FDA Fast Track Boosts Context Therapeutics’ CTIM-76 for Hard-to-Treat Ovarian Cancer
Context Therapeutics’ CTIM-76 wins FDA Fast Track Designation for platinum-resistant ovarian cancer. Phase 1a trial ongoing with interim data expected in June 2026.
/ 3 items
#CNTX↓
Biotech Stocks Update: ZBIO, SPRB, CNTX, OVID Ratings
Citi, H.C. Wainwright, JonesResearch, and LifeSci Capital share new ratings and price targets on Zenas BioPharma, Spruce Biosciences, Context Therapeutics, and Ovid Therapeutics.
Context Therapeutics: A Promising Cancer Drug Developer
A hidden cancer company, Context, got a top rating. Its ovarian cancer drug, CTIM-76, has key data coming in 2026.